CHARLESTON, S.C. , Jan. 25,
2023 /PRNewswire/ -- EverGlade Consulting
("EverGlade"), a national consulting firm, has helped Sabin Vaccine
Institute successfully secure up to $214
million in funding through a contract with the Biomedical
Advanced Research and Development Authority ("BARDA") to advance
the development and production of single-dose vaccine candidates
for Ebola Sudan and Marburg virus diseases.
Currently, there are no licensed vaccines against Ebola Sudan
and Marburg viruses, which cause hemorrhagic fever and kill
approximately half the people infected.
BARDA, part of the U.S. Department of Health and Human Services'
Administration for Strategic Preparedness and Response ("ASPR"),
will initially invest $35 million to
produce up to 100,000 doses of Ebola Sudan virus vaccine,
ChAd3-SUDV. These vaccines may be used as part of ongoing U.S.
preparedness efforts and in response to future global
The contract also includes funding to manufacture Sabin's
Marburg virus vaccine, ChAd3-MARV, which will generate doses that
could be used in trials and in response to a future Marburg virus
"I am excited that our team was able to contribute to this vital
BARDA initiative," said EverGlade Founder Eric Jia-Sobota. "This award addresses a
Andrew Stiles, Principal at
EverGlade, said, "The recent Ebola Sudan outbreak in Uganda emphasized the critical need for better
preparedness. It is great to see BARDA move quickly to partner with
industry to develop and secure readily available solutions to
address this threat and to bolster national preparedness and
response efforts for future public health emergencies."
About EverGlade Consulting
EverGlade Consulting is a national consulting firm helping
clients navigate the federal landscape. We work with
technology-driven companies whose focus is to secure non-dilutive
funding through the federal government. We offer services ranging
from opportunity identification and proposal support through the
implementation of systems to comply with federal regulations at
agencies including BARDA, ASPR, NIH, DTRA, JPEO, and DARPA.
For additional information about EverGlade Consulting,
For additional information about EverGlade's recent success,
View original content to download
SOURCE EverGlade Consulting